Teva Pharmaceuticals and AI-driven Immunai have entered into a partnership aimed at optimising clinical trials in immunology and immuno-oncology.

The multi-year collaboration will utilise Immunai’s proprietary immune cell atlas, AMICA, as well as its AI model, the Immunodynamics Engine (IDE), to improve clinical decision-making in Teva’s immunology trials.

Though financial details of the deal have not been disclosed, Immunai, which specialises in mapping the human immune system, outlined that the companies will focus on areas including drug mechanism of action, dose selection and biomarker analyses.

The partners could also expand the collaboration to cover broader aspects of Teva’s research and development portfolio.

Eran Harary, Senior Vice President of Global Early Clinical Development at Teva, said, “This collaboration will provide important insights into patient responses and treatment mechanisms in immunology and immuno-oncology, allowing us to optimise our clinical trials and improve outcomes for patients.”

Also commenting on the alliance, Immunai’s Chief Executive Officer, Noam Solomon, said, “Bringing a drug to market is inherently challenging, time-consuming and costly. Through our partnership with Teva, we are eager to utilise our AI-based engine, the IDE, to streamline this process and facilitate the delivery of new therapies to patients.”

The announcement comes less than two months after Immunai unveiled a multi-year collaboration with AstraZeneca for advanced clinical trial optimisation.

The agreement also focuses on clinical decision-making, including dose selection, mechanisms of action, patient responder versus non-responder analysis, as well as biomarker identification.

Vivolta, a specialist in medical electrospinning solutions, has entered a long-term partnership with UK-based Neurochase to manufacture electrospun micro-catheters for advanced brain therapies.

This partnership aims to enhance the treatment of neurological disorders, which affect nearly a billion people in the US and Europe.

Neurochase is developing a scalable system for delivering therapies directly to the brain using convection enhanced delivery (CED). This technique allows drugs to bypass the blood-brain barrier and reach deep brain structures through micro-catheters.

By generating a pressure gradient at the catheter tip, the drug is evenly distributed, maximising its therapeutic effect.

Denis Leissing, CEO of Vivolta, highlighted the significance of the partnership, “This partnership builds on our already successful product development work with Neurochase, establishing a long-term manufacturing relationship. It is a great example of our full suite of electrospinning solutions from product development to commercial manufacturing.”

He added, “We’re proud that our team’s expertise along with our unique and scalable MediSpinTM manufacturing system will help bring this high-performance micro-catheter to patients who will benefit.”

Neurochase’s CEO, Sharon Kane, echoed this sentiment, stating, “The Vivolta relationship has been hugely important in finding a solution to one of the most technically challenging components of the Neurochase delivery system. We are excited to be taking our transformative product forward together into large scale manufacture with such a knowledgeable, skilled and motivated team.”

The two companies first partnered in 2022 to develop the electrospun component of Neurochase’s micro-catheter delivery system.

Vivolta will exclusively manufacture these components using its automated MediSpinTM production system, known for its ability to produce electrospun medical products at scale.

Neurochase plans to begin clinical trials of its micro-catheter delivery system in 2025, collaborating with clients to treat conditions like Parkinson’s Disease, Huntington’s Disease, brain tumours and Fronto Temporal Dementia.